Moreover, the immunomodulatory nature of IFN-γ blockade raises concerns regarding heightened susceptibility to opportunistic infections and impaired host immune surveillance, which have led to the premature termination of several clinical trials due to adverse safety profiles. The gene discussed is IFNG; the disease is Opportunistic infection.